{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:35:02Z","timestamp":1790094902372,"version":"4.0.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.neo.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T04:38:51Z","timestamp":1558759131000},"page":"653-664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells"],"prefix":"10.1016","volume":"21","author":[{"given":"Moritz","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Altd\u00f6rfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schnitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Rolf","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korbinian Nepomuk","family":"Kropp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Rudolf","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut Rainer","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne Malaika","family":"Rittig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Gr\u00fcnebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"D\u00f6rfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2019.03.001_bb0005","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1038\/ncomms6659","article-title":"The role of protein clearance mechanisms in organismal ageing and age-related diseases","volume":"5","author":"Vilchez","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.neo.2019.03.001_bb0010","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.biocel.2012.07.011","article-title":"Proteasome deubiquitinases as novel targets for cancer therapy","volume":"44","author":"D'Arcy","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.neo.2019.03.001_bb0015","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/14728222.2013.815728","article-title":"Targeting the ubiquitin-proteasome system for cancer therapy","volume":"17","author":"Shen","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.neo.2019.03.001_bb0020","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1006\/bbrc.1995.2878","article-title":"Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells","volume":"217","author":"Imajoh-Ohmi","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.neo.2019.03.001_bb0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1042\/bj3170385","article-title":"Apoptosis induction resulting from proteasome inhibition","volume":"317","author":"Shinohara","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.neo.2019.03.001_bb0030","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1073\/pnas.94.3.855","article-title":"Activation of the cell death program by inhibition of proteasome function","volume":"94","author":"Drexler","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2019.03.001_bb0035","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1158\/1078-0432.CCR-06-0170","article-title":"United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2019.03.001_bb0040","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1158\/1078-0432.CCR-07-0871","article-title":"Bortezomib for the treatment of mantle cell lymphoma","volume":"13","author":"Kane","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2019.03.001_bb0045","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2019.03.001_bb0050","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.neo.2019.03.001_bb0055","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1042\/BST20140126","article-title":"Overcoming bortezomib resistance in multiple myeloma","volume":"42","author":"Murray","year":"2014","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.neo.2019.03.001_bb0060","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.neo.2019.03.001_bb0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12079-011-0121-7","article-title":"Proteasome inhibitors in cancer therapy","volume":"5","author":"Crawford","year":"2011","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.neo.2019.03.001_bb0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pharmthera.2014.11.002","article-title":"Deubiquitinase inhibition as a cancer therapeutic strategy","volume":"147","author":"D'Arcy","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.neo.2019.03.001_bb0075","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/nm.2536","article-title":"Inhibition of proteasome deubiquitinating activity as a new cancer therapy","volume":"17","author":"D'Arcy","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.neo.2019.03.001_bb0080","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","article-title":"A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance","volume":"123","author":"Tian","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.neo.2019.03.001_bb0085","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/bjh.13304","article-title":"Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenstrom macroglobulinaemia tumour cells","volume":"169","author":"Chitta","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.neo.2019.03.001_bb0090","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00262-018-2151-y","article-title":"The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma","volume":"67","author":"Kropp","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.neo.2019.03.001_bb0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41389-018-0086-y","article-title":"Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer","volume":"7","author":"Xia","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2019.03.001_bb0100","doi-asserted-by":"crossref","first-page":"63232","DOI":"10.18632\/oncotarget.18774","article-title":"A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers","volume":"8","author":"Cai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2019.03.001_bb0105","doi-asserted-by":"crossref","first-page":"8027","DOI":"10.1038\/s41598-017-08424-w","article-title":"The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5","volume":"7","author":"Oh","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.neo.2019.03.001_bb0110","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3324\/haematol.13783","article-title":"Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity","volume":"94","author":"Wang","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.neo.2019.03.001_bb0115","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.exphem.2013.11.010","article-title":"Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells","volume":"42","author":"Feng","year":"2014","journal-title":"Exp Hematol"},{"key":"10.1016\/j.neo.2019.03.001_bb0120","doi-asserted-by":"crossref","first-page":"18557","DOI":"10.3390\/ijms151018557","article-title":"Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system","volume":"15","author":"Sarhan","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neo.2019.03.001_bb0125","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2005-08-3494","article-title":"Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation","volume":"108","author":"Nencioni","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.neo.2019.03.001_bb0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.humimm.2006.12.005","article-title":"Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib","volume":"68","author":"Subklewe","year":"2007","journal-title":"Hum Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0135","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2567.2006.02487.x","article-title":"Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells","volume":"120","author":"Naujokat","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.neo.2019.03.001_bb0140","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0145","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","article-title":"Immunobiology of dendritic cells","volume":"18","author":"Banchereau","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.imbio.2004.03.005","article-title":"Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity","volume":"209","author":"Re","year":"2004","journal-title":"Immunobiology"},{"key":"10.1016\/j.neo.2019.03.001_bb0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0952-7915(97)80153-7","article-title":"Origin, maturation and antigen presenting function of dendritic cells","volume":"9","author":"Cella","year":"1997","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0160","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/icb.1997.35","article-title":"The role of dendritic cells in T cell activation","volume":"75","author":"Ni","year":"1997","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.neo.2019.03.001_bb0165","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/eji.1830270213","article-title":"Differentiation of human dendritic cells from monocytes in vitro","volume":"27","author":"Chapuis","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0170","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0092-8674(00)80693-5","article-title":"Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses","volume":"100","author":"Geijtenbeek","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.neo.2019.03.001_bb0175","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00262-011-1096-1","article-title":"The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors","volume":"61","author":"Schwarzbich","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.neo.2019.03.001_bb0180","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/leu.2008.301","article-title":"Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells","volume":"23","author":"Knodler","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2019.03.001_bb0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12964-015-0099-5","article-title":"The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells","volume":"13","author":"Gutknecht","year":"2015","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.neo.2019.03.001_bb0190","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.198.Supp.201.16","article-title":"Difference between Immature Dendritic Cells (imDCs) and Mature Dendritic Cells (mDCs) Derived from Human Monocytes","volume":"198","author":"Nagai","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0195","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1089\/089426801316970240","article-title":"Evaluation of phagocytic activity in human monocyte-derived dendritic cells","volume":"14","author":"Kiama","year":"2001","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.neo.2019.03.001_bb0200","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1084\/jem.189.3.447","article-title":"Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs","volume":"189","author":"Cyster","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.neo.2019.03.001_bb0205","doi-asserted-by":"crossref","first-page":"13803","DOI":"10.1074\/jbc.272.21.13803","article-title":"Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7","volume":"272","author":"Yoshida","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neo.2019.03.001_bb0210","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jlb.66.2.252","article-title":"Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines","volume":"66","author":"Dieu-Nosjean","year":"1999","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.neo.2019.03.001_bb0215","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N","article-title":"Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation","volume":"28","author":"Sallusto","year":"1998","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0220","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.4049\/jimmunol.161.3.1083","article-title":"Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties","volume":"161","author":"Sozzani","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0225","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1139\/W09-041","article-title":"In vitro maturation and migration of immature dendritic cells after chemokine receptor 7 transfection","volume":"55","author":"Xin","year":"2009","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.neo.2019.03.001_bb0230","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cytogfr.2007.10.004","article-title":"Dendritic cells and cytokines in human inflammatory and autoimmune diseases","volume":"19","author":"Blanco","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.neo.2019.03.001_bb0235","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1158\/2326-6066.CIR-13-0102","article-title":"Dendritic cells: master regulators of the immune response","volume":"1","author":"Mellman","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.neo.2019.03.001_bb0240","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.molmed.2013.04.005","article-title":"Autophagy: shaping the tumor microenvironment and therapeutic response","volume":"19","author":"Maes","year":"2013","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.neo.2019.03.001_bb0245","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/sj.leu.2404734","article-title":"Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells","volume":"21","author":"Straube","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.neo.2019.03.001_bb0250","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.neo.2019.03.001_bb0255","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.4049\/jimmunol.176.8.4757","article-title":"Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade)","volume":"176","author":"Schumacher","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0260","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.imbio.2009.06.018","article-title":"Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo","volume":"214","author":"Zinser","year":"2009","journal-title":"Immunobiology"},{"key":"10.1016\/j.neo.2019.03.001_bb0265","first-page":"4857","article-title":"Bortezomib inhibits bone marrow-derived dendritic cells","volume":"8","author":"Wang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.neo.2019.03.001_bb0270","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620717741860","article-title":"New and emerging therapies for acute and chronic graft versus host disease","volume":"9","author":"Hill","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.neo.2019.03.001_bb0275","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00262-013-1439-1","article-title":"A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells","volume":"62","author":"Sarhan","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.neo.2019.03.001_bb0280","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neo.2019.03.001_bb0285","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2019.03.001_bb0290","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1158\/1078-0432.CCR-11-2776","article-title":"Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders","volume":"18","author":"Bae","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.neo.2019.03.001_bb0295","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00262-013-1438-2","article-title":"Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients","volume":"62","author":"Hobo","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.neo.2019.03.001_bb0300","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00277-010-0931-3","article-title":"Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells","volume":"89","author":"Yang","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.neo.2019.03.001_bb0305","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00277-011-1219-y","article-title":"Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins","volume":"90","author":"Yang","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.neo.2019.03.001_bb0310","doi-asserted-by":"crossref","first-page":"41538","DOI":"10.18632\/oncotarget.14582","article-title":"A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma","volume":"8","author":"Jung","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2019.03.001_bb0315","first-page":"1337","article-title":"Dendritic cell-based therapy for mantle cell lymphoma","volume":"28","author":"Munger","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.neo.2019.03.001_bb0320","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1073\/pnas.0910609107","article-title":"Mature dendritic cells use endocytic receptors to capture and present antigens","volume":"107","author":"Platt","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neo.2019.03.001_bb0325","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.4049\/jimmunol.166.7.4312","article-title":"Regulatory activity of autocrine IL-10 on dendritic cell functions","volume":"166","author":"Corinti","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0330","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/eji.1830270526","article-title":"Effect of interleukin-10 on dendritic cell maturation and function","volume":"27","author":"De Smedt","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0335","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/intimm\/13.5.675","article-title":"Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines","volume":"13","author":"Yoshimura","year":"2001","journal-title":"Int Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0340","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2006-11-056010","article-title":"Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation","volume":"110","author":"Tas","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.neo.2019.03.001_bb0345","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.18632\/oncotarget.2904","article-title":"Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells","volume":"6","author":"Vogel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2019.03.001_bb0350","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7150\/jca.5046","article-title":"Dendritic cells in the cancer microenvironment","volume":"4","author":"Ma","year":"2013","journal-title":"J Cancer"},{"key":"10.1016\/j.neo.2019.03.001_bb0355","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.neo.2019.03.001_bb0360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CLM.2008.n.031","article-title":"Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma","volume":"8","author":"Kim","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.neo.2019.03.001_bb0365","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3109\/10428194.2014.941833","article-title":"Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant","volume":"56","author":"Li","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.neo.2019.03.001_bb0370","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.4049\/jimmunol.0901596","article-title":"The proteasome inhibitor bortezomib enhances the susceptibility to viral infection","volume":"183","author":"Basler","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.neo.2019.03.001_bb0375","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00262-018-2129-9","article-title":"The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells","volume":"67","author":"Dorfel","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.neo.2019.03.001_bb0380","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1182\/blood-2004-09-3556","article-title":"Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA","volume":"105","author":"Dorfel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.neo.2019.03.001_bb0385","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2010-05-284737","article-title":"Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis","volume":"117","author":"Hirai","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.neo.2019.03.001_bb0390","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/ijc.25635","article-title":"Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation","volume":"128","author":"Schmiedel","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.neo.2019.03.001_bb0395","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.3892\/or.2015.4296","article-title":"USP14 activation promotes tumor progression in hepatocellular carcinoma","volume":"34","author":"Huang","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.neo.2019.03.001_bb0400","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.intimp.2011.06.005","article-title":"Differential effects of the tumor necrosis factor alpha-blocker infliximab and etanercept on immunocompetent cells in vitro","volume":"11","author":"Thaher","year":"2011","journal-title":"Int Immunopharmacol"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558618306250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558618306250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T22:14:52Z","timestamp":1694902492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558618306250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1476558618306250"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2019.03.001","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}]}}